Neurocrine Biosciences Inc. (NBIX)

116.81
NASDAQ : Health Technology
Prev Close 116.48
Day Low/High 115.82 / 118.35
52 Wk Low/High 64.72 / 119.65
Avg Volume 814.00K
Exchange NASDAQ
Shares Outstanding 92.09M
Market Cap 10.73B
EPS 0.20
P/E Ratio 529.46
Div & Yield N.A. (N.A)

Latest News

A Bullish Play on Neurocrine Biosciences

A Bullish Play on Neurocrine Biosciences

Analysts weren't shy to defend the company after Tuesday's earnings.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Neurocrine Bio upgraded at Oppenheimer

Another Biotech Play

Another Biotech Play

Keep this one on the radar for a pullback buying opportunity.